Stryker Co. (NYSE:SYK) Stock Holdings Increased by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG lifted its position in shares of Stryker Co. (NYSE:SYK - Free Report) by 66.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,497 shares of the medical technology company's stock after purchasing an additional 998 shares during the period. J. Safra Sarasin Holding AG's holdings in Stryker were worth $899,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker during the 4th quarter worth $25,000. Rakuten Securities Inc. increased its position in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Stryker in the 4th quarter valued at about $30,000. BankPlus Trust Department purchased a new stake in shares of Stryker in the 4th quarter valued at about $33,000. Finally, Activest Wealth Management acquired a new stake in shares of Stryker in the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Up 0.8 %

SYK stock traded up $2.99 during midday trading on Tuesday, hitting $369.48. 345,947 shares of the company's stock were exchanged, compared to its average volume of 1,352,549. The firm has a 50 day moving average price of $367.37 and a 200-day moving average price of $373.51. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The stock has a market capitalization of $141.02 billion, a price-to-earnings ratio of 47.59, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business posted $3.46 EPS. On average, analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker's dividend payout ratio is presently 43.30%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SYK. Citigroup reiterated a "buy" rating and issued a $450.00 price objective on shares of Stryker in a research note on Wednesday, February 26th. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. StockNews.com lowered shares of Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, March 6th. Finally, Canaccord Genuity Group raised their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, Stryker has a consensus rating of "Moderate Buy" and a consensus price target of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.